Ozobax Ds (Baclofen) Patent Expiration, LOE Window & CMS Spending

Ozobax Ds (Baclofen) by Rosemount: FDA Orange Book LOE 2039-08-30, 19 AB generics, $32K 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorRosemount
FDA Application & PathwayN208193 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2039-08-30
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors19
2024 CMS Total Public Spend$32K
2024 Medicare Part D Spend$32K
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel